Cited by 851Autophagy in Disease and TherapyAlzheimer's disease research and treatmentsParkinson's Disease Mechanisms and Treatments

Compromised autophagy and neurodegenerative diseases

Menzies, Fiona M., Fleming, Angeleen, Rubinsztein, David C.·2015·Nature Reviews Neuroscience

Abstract

Most neurodegenerative diseases that afflict humans are associated with the intracytoplasmic deposition of aggregate-prone proteins in neurons and with mitochondrial dysfunction. Autophagy is a powerful process for removing such proteins and for maintaining mitochondrial homeostasis. Over recent years, evidence has accumulated to demonstrate that upregulation of autophagy may protect against neurodegeneration. However, autophagy dysfunction has also been implicated in the pathogenesis of various diseases. This Review summarizes the progress that has been made in our understanding of how perturbations in autophagy are linked with neurodegenerative diseases and the potential therapeutic strategies resulting from the modulation of this process.

Integrity signals

Registry

Crossref · 10.1038/nrn3961

Cites

190 of 190 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Endogenous defects in autophagy are associated with embryonic lethality, developmental defects, and multiple pathological disorders including neurodegeneration, cancer, and cardiovascular disorders.

    “and permanent or transient endogenous defects in autophagy have been associated with embryonic lethality, developmental defects, and multiple pathological disorders, including (but not limited to) neurodegeneration, cancer, and cardiovascular disorders [812–817].”
  • As age increases, autophagy and proteasomal degradation decline, leading to proteinopathies from aberrant protein misfolding and aggregation.

    “As we age, levels of autophagy and proteasomal degradation gradually decline, leading to proteinopathies, a result of aberrant protein misfolding and aggregation (Menzies et al., 2015; Nixon, 2013).”

    From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Menzies et al., 2015

  • Impaired autophagy with accumulated proteinopathies and impaired lysosome function/autophagy/mitophagy are common features of age-predisposed neurodegenerative diseases including AD, PD, HD, and tauopathies.

    “Impaired autophagy with accumulated proteinopathies are common pathological features in many age-predisposed neurodegenerative diseases, including AD, Parkinson’s disease (PD), Huntington disease (HD), and tauopathies. Importantly, impaired lysosome function and autophagy/mitophagy are common features among them (Kerr et al., 2017; Lou et al., 2019; Menzies et al., 2015; Nixon, 2013).”

    From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Menzies et al., 2015

  • Molecular and histopathologic analyses of patient tissues demonstrate mislocalized or accumulated autophagy machinery, pathogenic mutations underlying familial neurodegenerative diseases disable known autophagy-related factors, and genetically ablating autophagy effectors produces neurodegeneration in cell and animal model systems, supporting a role for autophagy dysfunction in age-related neurode

    “Molecular and histopathologic analyses of patient tissues demonstrate mislocalized or accumulated autophagy machinery, pathogenic mutations underlying familial neurodegenerative diseases disable known autophagy-related factors, and genetically ablating autophagy effectors produce neurodegeneration in cell and animal model systems [74–81], supporting a role for autophagy dysfunction in the devel”
  • We detect changes in genes associated with myelination and synaptic vesicle endocytosis, including DCX, SCAP, RB1CC1, ADSL and PACSIN1.

    “We also detect changes in genes associated with myelination and synaptic vesicle endocytosis, critical to sustain a high rate of synaptic transmission, including DCX104, SCAP105, RB1CC1106, ADSL107 and PACSIN1108 among others (Supplementary Information 2).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Menzies, F. M., Fleming, A., & Rubinsztein, D. C.
Affiliations
University of Cambridge (GB)
Corresponding author
Rubinsztein, David C.
Venue
Nature Reviews Neuroscience
Published
2015-05-20
Volume
16
Issue
6
Pages
345-357
ISSN
  • 1471-003X (ISSN-L)
  • 1471-0048
OpenAlex
W1565351177
Cited by
851
References
190
Citations by year
2026: 56 · 2025: 71 · 2024: 61 · 2023: 57 · 2022: 80 · 2021: 115 · 2020: 95 · 2019: 62 · 2018: 73 · 2017: 99 · 2016: 71 · 2015: 11
FWCI
11.00
Type
journal article
Language
en
Open access
closed
Locations
  • Nature reviews. Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
Funders
Wellcome Trust (100140, 095317)
Topics
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
autophagy, neurodegenerative diseases, macroautophagy, protein aggregation, mitochondrial dysfunction, mitochondrial homeostasis, neuroprotection, autophagy modulation, treatment options
MeSH terms
Animals, Autophagy, Humans, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review